Eli Lilly and Company broke ground this week on one of ten U.S. manufacturing sites — and the fifth location to produce domestic active pharmaceutical ingredients (API) — announced since 2020. As part of the company's $50 billion push to reshore medicine production to meet growing demand at home

Eli Lilly is set to pay InnoCare Pharma up to $3.35 billion to discover and develop compounds against upwards of five undisclosed targets.

Paul, Weiss advised Eli Lilly and Company on a strategic research collaboration and licensing agreement with InnoCare Pharma, a leading biopharmaceutical company focused on treatments for cancer and autoimmune diseases. Under the agreement, Lilly will provide China-based InnoCare up to $100 million in upfront and near-term payments, and up to approximately $3.25 billion in development and commercial milestone payments. InnoCare will also be eligible to receive royalties based on annual net product sales. The Paul, Weiss team was led by intellectual property partners Jeffrey Osterman and Meggin Bednarczyk.

Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare

InnoCare Pharma partners with Eli Lilly in drug research deal

La empresa china de biotecnología InnoCare Pharma anunció el día 24 que ha firmado un acuerdo de licencia y colaboración de investigación estratégica con EE. UU.…

At the close on September 23, 2026, Eli Lilly and Co. stock stood at USD 1,150.96 after trading betw

BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (

Eli Lilly inició la construcción de una planta de Houston valorada en 6.500 millones de dólares que fabricará Foundayo (o forglipron) y otros medicamentos, creando más de 600 puestos de trabajo como parte de su esfuerzo de 50.000 millones de dólares para relocalizar la fabricación de medicamentos en Estados Unidos.

Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.

View the basic LLY option chain and compare options of Eli Lilly and Company on Yahoo Finance.

David Ricks, CEO of Indianapolis-based drugmaker Eli Lilly and Co., said Indiana’s competitive standing has improved, but the state needs to do more to bolster its standing in several critical areas.

Lilly no longer publicly lists its earliest clinical programs. The move could buy the pharma giant time to test, kill and reposition drugs while competitors are still reading the board.

Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.

Eli Lilly and Co. stock closed at USD 1,172.05 on September 22, 2026, after a 0.61 percent gain. Q2